4i5m
From Proteopedia
(Difference between revisions)
Line 1: | Line 1: | ||
- | + | ==Selective & Brain-Permeable Polo-like Kinase-2 (Plk-2) Inhibitors that Reduce -Synuclein Phosphorylation in Rat Brain== | |
- | + | <StructureSection load='4i5m' size='340' side='right' caption='[[4i5m]], [[Resolution|resolution]] 1.80Å' scene=''> | |
- | { | + | == Structural highlights == |
+ | <table><tr><td colspan='2'>[[4i5m]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4I5M OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4I5M FirstGlance]. <br> | ||
+ | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=R78:4-{[(7R)-8-CYCLOPENTYL-7-ETHYL-5-METHYL-6-OXO-5,6,7,8-TETRAHYDROPTERIDIN-2-YL]AMINO}-3-METHOXY-N-(1-METHYLPIPERIDIN-4-YL)BENZAMIDE'>R78</scene></td></tr> | ||
+ | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">PLK2, SNK ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr> | ||
+ | <tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Polo_kinase Polo kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.11.21 2.7.11.21] </span></td></tr> | ||
+ | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4i5m FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4i5m OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4i5m RCSB], [http://www.ebi.ac.uk/pdbsum/4i5m PDBsum]</span></td></tr> | ||
+ | </table> | ||
+ | <div style="background-color:#fffaf0;"> | ||
+ | == Publication Abstract from PubMed == | ||
+ | Polo-like kinase-2 (Plk-2) has been implicated as the dominant kinase involved in the phosphorylation of alpha-synuclein in Lewy bodies, which are one of the hallmarks of Parkinson's disease neuropathology. Potent, selective, brain-penetrant inhibitors of Plk-2 were obtained from a structure-guided drug discovery approach driven by the first reported Plk-2-inhibitor complexes. The best of these compounds showed excellent isoform and kinome-wide selectivity, with physicochemical properties sufficient to interrogate the role of Plk-2 inhibition in vivo. One such compound significantly decreased phosphorylation of alpha-synuclein in rat brain upon oral administration and represents a useful probe for future studies of this therapeutic avenue toward the potential treatment of Parkinson's disease. | ||
- | + | Selective and Brain-Permeable Polo-like Kinase-2 (Plk-2) Inhibitors That Reduce alpha-Synuclein Phosphorylation in Rat Brain.,Aubele DL, Hom RK, Adler M, Galemmo RA Jr, Bowers S, Truong AP, Pan H, Beroza P, Neitz RJ, Yao N, Lin M, Tonn G, Zhang H, Bova MP, Ren Z, Tam D, Ruslim L, Baker J, Diep L, Fitzgerald K, Hoffman J, Motter R, Fauss D, Tanaka P, Dappen M, Jagodzinski J, Chan W, Konradi AW, Latimer L, Zhu YL, Sham HL, Anderson JP, Bergeron M, Artis DR ChemMedChem. 2013 Aug;8(8):1295-313. doi: 10.1002/cmdc.201300166. Epub 2013 Jun, 21. PMID:23794260<ref>PMID:23794260</ref> | |
- | + | ||
- | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
- | + | </div> | |
- | == | + | ==See Also== |
- | + | *[[Serine/threonine protein kinase|Serine/threonine protein kinase]] | |
+ | == References == | ||
+ | <references/> | ||
+ | __TOC__ | ||
+ | </StructureSection> | ||
+ | [[Category: Human]] | ||
[[Category: Polo kinase]] | [[Category: Polo kinase]] | ||
[[Category: Adler, M.]] | [[Category: Adler, M.]] | ||
Line 26: | Line 39: | ||
[[Category: Fauss, D.]] | [[Category: Fauss, D.]] | ||
[[Category: Fitzgerald, K.]] | [[Category: Fitzgerald, K.]] | ||
- | [[Category: Galemmo | + | [[Category: Galemmo, R A.]] |
[[Category: Hoffman, J.]] | [[Category: Hoffman, J.]] | ||
[[Category: Hom, R K.]] | [[Category: Hom, R K.]] |
Revision as of 05:51, 8 October 2014
Selective & Brain-Permeable Polo-like Kinase-2 (Plk-2) Inhibitors that Reduce -Synuclein Phosphorylation in Rat Brain
|
Categories: Human | Polo kinase | Adler, M. | Anderson, J P. | Artis, D R. | Aubele, D L. | Baker, J. | Bergeron, M. | Beroza, P. | Bova, M P. | Bowers, S. | Chan, W. | Dappen, M. | Diep, L. | Fauss, D. | Fitzgerald, K. | Galemmo, R A. | Hoffman, J. | Hom, R K. | Jagodzinski, J. | Konradi, A W. | Latimer, L. | Lin, M. | Motter, R. | Neitz, R J. | Pan, H. | Ren, Z. | Ruslim, L. | Sham, H L. | Tam, D. | Tanaka, P. | Tonn, G. | Truong, A P. | Yao, N. | Zhang, H. | Zhu, Y L. | Kinase inhibitor | Parkinson's disease | Synuclein | Transferase-transferase inhibitor complex